Background: Differential diagnosis of people presenting with mild cognitive impairment (MCI) that will progress to Alzheimer's disease (AD) remains clinically challenging. Current criteria used to define AD include a series of neuropsychological assessments together with relevant imaging analysis such as magnetic resonance imaging (MRI). The clinical sensitivity and specificity of these assessments would be improved by the concommitant use of novel serum biomarkers. The branched chain aminotransferase proteins (BCAT) are potential candidates as they are significantly elevated in AD brain, correlate with Braak Stage and may have a role in AD pathology.
INTRODUCTION
tau and p-tau or using PET scanning have credible sensitivity and specificity in predicting the conversion from MCI to AD but have yet to be adopted in a routine clinical setting due to expense, lack of expertise and relevant hardware [18] [19] [20] [21] .
Together with the development of CSF biomarkers, there has been a drive to develop bloodbased biomarkers, which are less invasive with potential for a wider clinical utility. Numerous candidates have emerged including plasma Aβ1-42 and the ratio of Aβ1-42/Aβ1-40 [22] , plasma phospholipids [23] , plasma proteins [24] [25] [26] [27] , microRNA expression profiling [28] and multianalyte platforms targeting neuroinflammatory changes [29, 30] and protein panels [31] . In an effort to target multiple affected pathways a number of research groups have also used proteomics or metabolomics platforms to predict AD onset [32] . These assays, combined with high throughput mass spectroscopy analysis, offer exciting new opportunities to better diagnose cognitive impairment. However, there are still considerable challenges for current blood-based biomarkers which includes lack of reproducibility between studies (most likely due to a lack of assay development or validation), an inconsistent approach to study design that spans from sample collection through to reporting and biomarker specificity.
The cytosolic isoform is expressed in the soma and proximal dendrites of glutamatergic and GABAergic neuronal cells, supporting its role in contributing to the storage and metabolic pools of glutamate [34] . The mitochondrial form was shown to be expressed in the brain vasculature, particularly in endothelial cells, where a supporting role for astrocytic regulation of glutamate uptake has been proposed. These proteins were found to be significantly increased in the hippocampal, frontal and temporal region of AD brain, where BCATm correlated with Braak stage, indicating a link with disease severity [35] . In other studies, it has been shown that a mutation in the BCAT2 gene results in the clinical presentation of individuals with mildcognitive impairment (MCI) and brain lesions together with hyperleucinaemia and hypervalinaemia, supporting a role for BCAT in sustaining optimal cognitive function [36] .
In this study, we show for the first time that perturbations in BCAT/glutamate metabolism observed in AD brain is reflected in serum. We present data that the amino acid, glutamate, a product of BCAT metabolism, is found to be significantly increased in serum AD. These analytes also show correlation with several neuropsychological tests and structural MRI analysis, indicating that the BCAT protein and glutamate show promise as early diagnostic biomarkers. Therefore, because BCAT is intrinsically linked with metabolic pathways that are perturbed in AD it has the advantage over other blood markers in that it is associated with AD disease progression. Moreover, we have assessed whether the predictive power of BCAT as a blood biomarker of AD could be increased by combining with neuropsychology and neuroimaging scores, offering a combined assessment of AD pathology.
MATERIALS AND METHODS

Materials
Rabbit polyclonal antibodies to BCATc and BCATm were purchased from Insight Biotechnology (Peterborough, UK). The specificity of the BCATc and BCATm antibodies has been validated for western blotting [35, 36] . Chemiluminescent substrate was purchased from Millipore (Watford, UK) and rabbit polyclonal antibody to transferrin from Abcam (Cambridge, UK).
Participants
The study was approved by North Somerset and South Bristol Research Ethics Committee, Bristol, UK. All experiments were carried out in accordance with ethical and NHS governance guidelines and approvals. University of Bristol agree in principle to anonymised data sharing with external researchers and each data request is assessed individually. Participants with the capacity to consent were recruited from the following local and national volunteer registers: and have memory deficits demonstrated on at least one of their clinical cognitive assessments.
2) Patients diagnosed with MCI who have either symptoms of amnesia or >1 SD impairment below expected for age performance in episodic memory clinical cognitive tests. 3) Healthy participants age-matched to patients above. Exclusion criteria 1) patients with dementia likely to be of a different aetiology; 2) participants taking medication likely to interfere significantly with cognitive function (except cholinesterase inhibitor and memantine used routinely in dementia) 3) participants with physical limitations such that they will not be able to carry out the requirements of the study; 4) participants with a history of significant claustrophobia or previous panic or claustrophobia while in an MRI scanner; 5) participants with significant other neurological or psychiatric illnesses likely to interfere with performance on the task. All participants underwent a screening interview to assess demographic factors thought to impact on cognitive decline (IQ, history of head trauma, epilepsy, smoking and alcohol intake) ( Table   1 ). There was no significant difference between AD, MCI and control groups with respect to most parameters, however, there was a significant difference with respect to years of education and IQ score. For blood analysis a number of people were unable to provide a sample, therefore a total of 46 controls, 17 MCI and 13 AD were recruited for this aspect of the study.
ApoE genotyping
Genomic DNA was extracted from 300 µL of whole blood using UltraClean® Blood DNA isolation Non-Spin Kit (Cambio) and detected using ultraviolet spectrophotometry (Thermo Scientific™ NanoDrop™, Loughborough, UK). ApoE genotyping was performed using a PCD-RFLP method, previously described by Hixson and Vernier, 1990 [37,38] . Briefly, DNA was amplified by PCR using oligonucleotide primers (Eurofins Genomics; upstream primer: 5ʹ-TCC AAG GAG CTG CAG GCG GCG CA -3ʹ, downstream primer: 5ʹ-ACA GAA TTC GCC CCG GCC TGG TAC ACT GCC A -3ʹ). ApoE was amplified using a PTC-200 Peltier Thermal Cycler at 94°C for 12 minutes followed by 48 cycles at 94°C for 1 minute, 65°C for 1 minute and a final extension of 75°C for 1 minute. The PCR product was visualised on a 2.5% ethidium bromide agarose gel at 227 bp before overnight digestion with HhaI in a total volume of 50 µL at 37°C. Digestion products were visualised using a 3.5% Metaphor agarose gel (Lonza). The protein concentration of serum samples from 46 controls, 17 MCI and 15 This was coupled with an Agilent 6460 triple quadrupole mass spectrometer for tandem mass spectroscopy (Agilent JetStream electrospray ionisation) and multiple reaction monitoring.
Western blot analysis of serum samples
Samples were injected onto an Agilent ZORBAX Eclipse Plus C18 column (4.6 mm x 150 mm, formic acid and mobile phase B = 100% acetonitrile. Gradient elution was used to separate each amino acid. The amino acids and their internal standards were monitored and their peak area ratio relative each other calculated allowing for the correction of transition overlap between neutral leucine and isoleucine.
Cognitive Assessment
Participant carried out a battery of tasks designed to probe hippocampal function as well as tests of wider cognitive function. Tests that were performed as part of the experimental procedure included: 1) Montreal cognitive assessment (MoCA, as a global cognitive screen).
2) Paired Associate Learning from CANTAB as a pattern/spatial memory task widely used and thought to be a "hippocampal" task -used as an early marker of AD. 3) Adapted verbal learning task (similar to Hopkins Verbal Learning Task) testing memory over 30 minutes, 24 hours, 2, 7 and 14 days [40] .
MRI
All participants were scanned with Siemens Magnetom Skyra 3T MRI system using a 32Ch head coil. The MRI protocol was as follows: 3D T1-weighted MRI was collected with MPRAGE: coronal, TR 2200 ms, TE 2.42 ms, TI 900 ms, flip angle 9°, resolution 0.34 x 0.34 x 1.60 mm 3 (after 2-fold interpolation in-plane), matrix size 540 x 640 x 144 (after 2-fold interpolation in-plane), GRAPPA factor 2, time 5:25. Quantitative T2 images were acquired with a multi-contrast spin-echo sequence: coronal, TR 4500, TE 12 ms, number of echoes 10, echo spacing 12 ms, resolution 0.34 x 0.34 x 1.7 mm 3 (after 2-fold interpolation in-plane, and inclusive of 15% slice gap), matrix size 540 x 640, 34 slices, GRAPPA factor 2, time 11:07.
MRI volumetric analyses
Total brain, gray matter, white matter and CSF space volumes were determined using FSL routines (http://www.fmrib.ac.uk/fsl). Morphometry of hippocampus and its sub-regions were determined from T2 images using the manual protocol by Wood et al (2015) [41]. This protocol provides volumes for 6 subfields as follows: CA1, CA2, CA3, dentate gyrus, subiculum, hippocampal and entorhinal.
Statistical Analysis
The data was screened for its accuracy and validity and for any potentially influential or outlying observations which may otherwise unduly impact results. A between-participants analysis of variance for a one-way design, with a post-hoc application of Tukey's HSD pairwise test was used to assess for differences between Control/MCI/AD for BCATc, BCATm, amino acids, brain sub-volumes, and the cognitive data. Residuals under each ANOVA were examined to ensure they did not grossly deviate from the assumption of errors being independent identically distributed normal deviates. Pearson's correlation coefficient was used to assess the strength and direction of correlations among quantitative measures.
MoCA scores were used in a linear discriminant analysis to develop a baseline model to discriminate between Control/MCI/AD. We sought to extend this baseline model to determine whether the inclusion of BCATc, BCATm, the amino acids and brain sub-volumes would improve the discrimination between groups. Accuracy of discrimination was determined using leave-one-out cross-validation.
To account for the putative ordering of outcome 
RESULTS
Clinical data and ApoE Genotyping
Clinical data for each participant was determined at baseline and summarised in Table 1 .
There was a significant difference between groups (Control/MCI/AD) with respect to the age they left school, years of education and reports of head injury. Overall, the majority of patients (49%) presented with ApoE 3/3 genotype, considered a 'neutral' genotype, with 9% patients with e4/4, linked to AD and the remainder of the patients were heterozygotes. There were no participants with the e2/2 genotype, which shows a protective effect against AD [36] .
Interestingly, only 1 participant that was determined to have probable AD was shown to have the e4/4 genotype with 4 other showing a heterozygote pattern. However, there were a number of participants that were designated controls that did carry the e4/4 genotype.
Moreover, in some control patients, in particular with the ApoE4 genotype (where ApoE4 carriers have a 40% greater risk of developing AD) levels of their BCAT proteins were increased, indicating that these patients show common emerging profiles similar to those with MCI or AD. We hypothesise that in this instance these biomarkers may have scope as predictors of preclinical AD.
Increased BCAT expression in AD serum reflect AD brain patterns
Blood analysis revealed that the BCAT proteins were increased in patients with AD compared to healthy controls (p < 0.0001 and p=0.0003, BCATc ( Figure 1A ) and BCATm ( Figure 1B) , respectively) and clearly distinguished between groups ( Table 2 ). The data show that in some MCI cases their blood profiles reflected changes similar to that observed for AD ( Figure 1A 
Increased levels of glutamate in AD serum differentiates between groups
The blood amino acids, in particular the branched chain amino acids (BCAAs), glutamate and the aromatic amino acids (AAAs) showed an altered amino acid profile in the plasma from AD patients relative to controls. In particular, there was an increase in the concentration of glutamate from control to MCI to AD (Table 3) . Table 3 summarises mean levels and within group variation for the amino acid levels. In the sample, mean levels of Isoleucine, Leucine,
Valine and Tyrosine significantly differ between conditions. In the control compared with MCI a pairwise comparison showed there was a significant difference between the BCAAs Isoleucine (p=0.0077), Leucine (p=0.0141), and valine (p=0.0063), indicating that these amino acid profiles may be early predictors of preclinical AD ( Figure 2 ).
Differentiation between participant groups
The hippocampus of AD patient displays marked atrophy compared to control ( Figure 3 ). The MRI data indicate that while reduction of total hippocampal volume is evident in both MCI and mild AD, the volume reduction concerns primarily CA1, dentate gyrus and subiculum and that tissue loss in these sub-regions is uneven. As described we have administered versatile cognitive neuropsychology tests to the same participants to gain understanding of functional consequences of the described morphometric changes in the hippocampus and its sub- Mean levels for CA1, Dentate Gyrus, Subiculum, Hippocampal, and Entorhinal monotonically decrease with progression from Control, to MCI, to AD, and these trends are statistically significant ( Table 5 ). In all cases for CA1, CA2, Dentate Gyrus, Subiculum and Hippocampal, the mean levels in Control are significantly higher than MCI, and AD (p < 0.05), but with no significant difference between MCI and AD (p > 0.05).
BCATm and BCATc are significantly correlated, r = 0.851, p < 0.001, and are significantly correlated with MoCA, r = -0.317, p = 0.006, and r = -0.388, p = 0.001, respectively. Glutamate is not significantly correlated with BCATm (r = 0.096, p = 0.442). However, Glutamate is significantly correlated with BCATc (r = 0.303, p = 0.013) and is significantly correlated with the inclusion of any of, BCATc (p = 0.001), Glutamate (p = 0.035), Leucine (p = 0.019), Valine (p = 0.008), Phenylalanine (p = 0.030), Isoleucine (p = 0.044), or Tyrosine (p = 0.005).The inclusion of BCATm is not deemed to be statistically significant (p = 0.054) in this sample. (p = 0.011), Glutamate (p = 0.003), Leucine (p = 0.045), Valine (p = 0.048) but with levels of predictive accuracy notably lower when compared with the models using MoCA.
For blood markers only, BCATc, BCATm and Glutamate in combination and individually show good discriminatory powers (Table 7) . For MoCA alone, sensitivity and specificity were 0.947 and 0.900 with respect to AD. This ordinal logistic regression model was significantly improved when combined with BCATc or the amino acids (Table 7) . Of note is the measure of BCATc with MoCA which improved sensitivity for AD to 1.00 and specificity to 0.902, compared with sensitivity of 0.917, and specificity of 0.969 for BCATm and MoCA in combination. In contrast, the MoCA models were not greatly improved by the inclusion of the Dentate Gyrus subfield volume.
DISCUSSION
Biomarkers have a wide range of applications in clinical research, drug discovery and clinical diagnosis. While dementia biomarkers in body fluids are highly promising, justifying population-based studies, prediction value could be hugely increased by combining with other assessment modalities. Our data suggest that the predictive power of BCAT or glutamate is increased by either structural information from MRI of vulnerable brain structures [14] and/or neuropsychological tests [11] . Here, in this collaborative study, across three disciplines, we address the potential of BCAT and glutamate to predict AD with our main goal of working towards the early diagnosis of AD.
The key aspects of the current guidelines recognize that AD progresses on a spectrum with three stages, an early, preclinical stage with no symptoms, a middle stage of MCI and a final stage marked by symptoms of dementia [11] . The potential use of biomarkers as indicators of underlying AD pathology has been recognized formally in diagnostics criteria [11] .
However, in these guidelines the recommendation is that the use of biomarkers is still focused on research rather than in a clinical setting. In our study, blood analysis revealed that the BCAT proteins were increased in patients with AD compared to healthy controls and clearly distinguished between groups (Figure 1 and Table 2 ). Previous studies by our group have shown that the levels of the BCAT proteins, which regulate BCAA and glutamate metabolism, are increased in the hippocampus, frontal and temporal cortex in AD relative to matched control brains [35] . As discussed, the upregulation of BCATm correlated with Braak stage, suggesting that the level of this enzyme is directly related to the progression of the disease [35] . Interestingly, there is no significant difference between mean BCAT levels in MCI compared to the more severe AD participants. This argues that BCAT may reflect early pathological changes in the brain supporting our findings in brain tissue. This analysis correlated with the MoCA score and with various neuropsychological tests and several indicators of hippocampal volume reduction, suggesting that BCAT is a valid measure of AD pathogenesis ( Figure 4 and Table 7 ).
Studies from cell and animal models suggest that increased levels of BCATs may, at least initially, be neuroprotective or when considering glutamatergic signalling compensatory [35] .
Using a rat model of brain injury, upregulation of BCATc was clearly evident in neurons that had normal morphology, despite the fact that overall levels correlated with the extent of cell death [42] . A potential underlying mechanism could be related to regulation via the brainderived neurotrophic factor (BDNF), important in mediating neuronal survival [43] . In response to BDNF treatment, mRNA fingerprinting showed that BCATc was significantly upregulated [44] . In a separate study, the authors demonstrated that upregulation of BCATc mRNA in adult BNDF transgenic mice was particular to the parietal cortex, the hilus, and CA3
hippocampal subfield [45] . Our group previously showed that in AD brain similar regional upregulation of BCAT was observed and in general the neurons that were immunopositive for BCATc in the human brain tissue also appeared morphologically intact [35] .
However, sustained increased BCAT expression could increase the production of glutamate and exacerbate neuronal excitotoxicity, potentially contributing to cell death. Here, we show that there is a significant increase in the levels of serum glutamate that monotonically increased across the three groups ( Figure 3A) . Interestingly, proton magnetic resonance ( 1 H MRS) assessment of metabolites such as glutamate showed a decrease in hippocampal brain glutamate between control, MCI and AD participants [46] . Glutamatergic neurons located in the hippocampus, frontal, temporal and parietal cortex have been reported to be severely affected in AD relative to similar neurons in the motor and sensory cortex and considered a possible early event in the pathogenesis of the disease [47, 48] . A recent study has indicated that measures of the glutamatergic system i.e. reduced glutamatergic presynaptic bouton density, correlated with MCI more so than Aβ or Tau [49] . More important and potentially relevant to the current study was that this study reported an increase in glutamatergic synapses in individuals with MCI. The authors interpreted this increase as a compensatory mechanism to counteract the effects of pre-existing synaptotoxicity to improve transmission probability. Therefore, whilst a neuroprotective has been proposed for increased BCAT, its increased expression may also reflect a compensatory mechanism. The glutamate/glutamine cycle has received much attention as several aspects of this cycle are perturbed in AD brain including 1) Reduced levels of VGLUT1 and 2 in the prefrontal cortex of individuals with AD [50] 2) Aβ peptides accumulate more in VGLUT1/2-containing terminals than in non-VGLUT terminals indicating a preferential targeting of these type of neurons [51] 3) Synaptic glutamate transporter defect, an early sign in disease pathology [52] 4) Low levels of glutamate synthetase in astrocytes [53, 54] . This extensive evidence together with our data supports a role for BCAT and glutamate as early indicators of disease pathology.
Levels of BCAAs were tested because excess or limiting dietary BCAA causes neurological dysfunction, reducing cognitive function, however, the mechanisms underlying these links are not entirely understood and require further investigation. Several studies have reported the amino acid profiles in the CSF and plasma of individuals with MCI and AD, generating a mixed data set with wide variability possibly due to study design, methodologies or instrumentation [55] . We show here that levels of leucine, isoleucine and valine independently and together are lower in Control relative to MCI and AD participants. Based on pairwise comparisons there is a significant increase in the BCAAs in MCI relative to Control subjects, where monitoring a change over time holds promise as a predictor of AD. A genome-wide association study (GWAS) identified several genetic variants that are associated with increased BCAA levels [52] . Using Mendelian randomization (MR) Larsson and Markus suggested that individuals with a genetic predisposition to raised plasma isoleucine were positively associated with AD [53] . More recently, the BCAAs have been shown to have a predictive value for the development of new-onset diabetes up to 12 years after the baseline examination, which incidentally has a 50% increased risk of developing AD [56, 57] . Conversely, in other conditions such as liver disease [58] , traumatic brain injury (TBI) [59,60] and sepsis [61], levels of blood BCAAs are low. In TBI, where brain glutamate is low, the plasma concentrations of the BCAAs are also decreased, whereas the concentrations of the AAA's (phenylalanine, tryptophan and tyrosine) are increased [57] . In patients recovering from TBI, BCAA supplementation has demonstrated a therapeutic benefit with improved cognition. Similar reports have been highlighted when treating chronic hepatic encephalopathy and sepsis. In patients with liver disease, supplementation with BCAAs reduces ascites [62] , hepatic encephalopathy [63] and malnutrition [64] . In Huntington's disease, plasma BCAAs are significantly decreased [65] , and correlate with disease severity over time [66] . These clinical presentations highlight how sub-optimal or chronically high levels of BCAAs affect brain function and how the BCAT metabolic proteins and activity are important to cognitive wellbeing. It is important to note that whilst alterations in BCAT and BCAA metabolism are associated with various disorders, further studies are required to better determine the optimal level required for cognitive well-being, which will better inform clinical practice.
In a recent case report, a patient presented with hypervalinaemia, hyperleucine-isoleucinemia, headaches, and MCI with brain white matter lesions [36] . Traditionally, one would relate increased levels of blood BCAAs with Maple Syrup Urine disease, an autosomal recessive disorder, caused by a deficiency of the branched-chain α-keto acid dehydrogenase complex (BCKDC) [67] . The patient was found to have two heterogeneous BCAT2 mutations, including c.509G-A and c.790G-A, suggesting that when BCAT2 is mutated, BCAA metabolism is perturbed, cognition is impaired and brain lesions develop. When the patient was treated with Vitamin B6 the symptoms subsided and the lesions decreased. This is particularly relevant to AD as a study that used vitamin B supplementation over 2 years showed how accelerated brain atrophy in elderly subjects with MCI was slowed by 30%, which corresponded to a decrease of 31.7% in total homocysteine levels [68] . In their report the authors assumed that the reduction was directly related to the homocysteine pathway, however, BCAT is also a vitamin B-dependent enzyme and may also be important in this mechanism. We propose that BCAT is upregulated in a neuro-protective manner that responds to nutritional or redox changes in the cell. However, as with most biological systems, an imbalance in metabolism could generate secondary consequences, such as increased glutamate production leading to neuronal toxicity, a recognised contributing factor to AD pathology. If BCATis oxidised it could assume a moonlighting neurotoxic role [69] . Together both the BCAT proteins and their metabolites hold promise as markers of AD pathology and may also serve as targets for future therapy-related approaches.
In the current study, serum analyses were conducted together with advanced MRI imaging and neuropsychology tests to detect alteration in the hippocampus in MCI and AD participants.
The MRI data have indicated that while reduction of total hippocampal volume is evident in both MCI and AD brains, the volume reduction concerns primarily CA1, dentate gyrus and subiculum. We have administered versatile cognitive neuropsychology tests to the same participants to gain understanding of functional consequences of the above described morphometric changes in the hippocampus and its sub-regions. Here, we show that the morphological changes detected by MRI analysis correlates with MoCA (assessment of longterm memory) ( Table 6 ) indicating that both these measures can be used in assessment of control compared with AD participants. The sensitivity and specificity values reported in table   7 show that baseline models utilising either MoCA or Dentate Gyrus are improved by incorporating the BCAT proteins or the amino acids. Diagnostically the most clinically relevant assays to date include measurement of CSF Aβ1-42 tTau, pTau and the Aβ/total tau index (ATI). Using combinations of these biomarkers the clinical sensitivity and specificity can vary between studies and can reach values up to 90% and 85%, respectively [for review see 70] .
However, current studies measuring these parameters in blood have not generated substantial data in support of their diagnostic use. Other studies favour multi-analyte approaches such as the Luminex-based platform that identified 30 protein markers in discriminating AD from controls (AUC=0.95) [71] indicating that a panel approach has potential to better delineate between participant groups.
In conclusion, using this proof of concept model we have shown that measurement of BCATc, BCATm and the amino acids increased the sensitivity and specificity of MoCA analysis in correctly identifying participants free of AD pathology (90%) and those with the disease to 100% accuracy. This analysis indicates that there is a high degree of information overlap 
